No EMA (European Medicines Agency) or MHRA approval exists for any indication
The landmark SURMOUNT-OSA trial found that tirzepatide reduced the apnea-hypopnea index (AHI), the standard measure of sleep apnea severity, by approximately 50 to 60 percent at 52 weeks (Malhotra et al., New England Journal of Medicine , 2024)
[34] [35] In addition, unlike the case of peripheral administration, intranasal oxytocin has a central duration of at least 2.25 hours and as long as 4 hours
Cancer Immunol Immunother
Once symptoms improve, a lower dose might be used
DAC (Drug Affinity Complex) is a modification that lets the peptide bind to albumin in your blood, extending its half-life from ~30 minutes to ~8 days